Organization (Industry)
BAVARIAN NORDIC A/S
ClinicalTrials.gov lists BAVARIAN NORDIC A/S as lead sponsor of 57 trials. It has 17 active development programs and 6 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Unknown author Unknown author, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers BAVARIAN NORDIC A/S: 57 lead-sponsored trials and 4 legal-entity registrations.
Disease areas (25)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Smallpox | 13 |
| Chikungunya Fever | 8 |
| HIV Infections | 7 |
| Mpox, Monkeypox | 6 |
| Cholera | 5 |
Showing 5 of 25 disease areas.
Trials by start year as sponsor or collaborator (25)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 6 |
| 2024 | 1 |
| 2023 | 1 |
| 2022 | 3 |
| 2021 | 4 |
| 2020 | 2 |
| 2019 | 4 |
| 2018 | 9 |
| 2017 | 2 |
Showing 10 of 25 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 6 trials still running at the 2026-10-09 snapshot; registered median of 14 months across 46 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (17)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| CHIKV VLP vaccine | Chikungunya Fever | Phase 3 | 2 |
| CHIKV VLP vaccine booster | Chikungunya Fever | Phase 3 | 1 |
| PXVX0200 | Cholera | Phase 3 | 3 |
| CHIKV VLP/adjuvant | Chikungunya Fever | Phase 3 | 2 |
| PXVX0200 Lot A | Cholera | Phase 3 | 1 |
Showing 5 of 17 active programs.
Approved assets (6)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| IMVAMUNE | 17 |
| VAXCHORA (Cholera Vaccine, Live, Oral) | 1 |
| COMIRNATY | 1 |
| ATEZOLIZUMAB | 1 |
| NIVOLUMAB | 1 |
Showing 5 of 6 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 67% hit target (n=21) | 30% on time (n=20) |
Journals published in (31)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Vaccine | 13 |
| PloS one | 5 |
| The Journal of infectious diseases | 4 |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 3 |
| PLoS neglected tropical diseases | 3 |
Showing 5 of 31 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 133 | 14 | 2025-08-19 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 1 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Bavarian Nordic A/S | Kvistgaard, DK | EMA, FDA, Health Canada |
Organization relationships (22)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 4 |
| JPM CBRN Medical | Co sponsors trial with | 2 |
| Indiana University | Co sponsors trial with | 1 |
| George Mason University | Co sponsors trial with | 1 |
| Pharmaceutical Product Development (United States) | Co sponsors trial with | 1 |
Showing 5 of 22 relationships.
Latest dated events (208)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-05-26 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-15 | FDA inspection | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2025-10-27 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-08-19 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-06-23 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 208 events.
Biomarker capability evidence (197)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALK | Trial sponsor | Named in trial inclusion criteria |
| ALK | Trial sponsor | Named in trial inclusion criteria |
| BLVRB | Trial collaborator | Named in trial inclusion criteria |
| BRAF | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 197 evidence rows.
On Scientist.com
BAVARIAN NORDIC A/S is listed as a research supplier in the Scientist.com network.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, fda import refusals, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.
Work with Bavarian Nordic GMBH on Scientist.com
For prices, more details, or to contact Bavarian Nordic GMBH, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.